Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 nipocalimab versus placebo in adults with moderate to severe Sjögren's disease
NL-OMON59937Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Change from baseline in ClinESSDAI score at Week 48. Started Jan 2026; status: completed.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59937.